To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.

开始日期2023-02-01

申办/合作机构

Caris Life Sciences, Inc.

NCT03834220

/ Terminated临床2期

A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3

The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.

开始日期2019-03-22

申办/合作机构

Debiopharm International SA

[+2]

NCT02967770

/ Withdrawn临床2期IIT

A Randomized Phase II Trial Comparing Molecularly Tailored Therapy to Physician's Discretion Standard of Care as Second-Line Therapy for Patients With Metastatic Pancreatic Cancer

The purpose of this study is to determine whether molecularly tailored therapy can improve the efficacy of treatment when compared to standard chemotherapy combinations for patients with metastatic pancreatic cancer receiving their second line of therapy for metastatic disease.

开始日期2016-11-01

申办/合作机构

Georgetown University

[+8]

100 项与 Caris Life Sciences, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Caris Life Sciences, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Caris Life Sciences, Inc. 相关的文献（医药）

2025-05-12·LEUKEMIA & LYMPHOMA

Mutational landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) involving the central nervous system

Article

作者: Burtsev, Anton ; Evans, Mark G. ; Gamayo, Ashley ; Rezk, Sherif A. ; Haghighi, Nahideh ; Shestakova, Anna ; Zhang, Ying ; Quintero-Rivera, Fabiola ; O’Brien, Susan ; Chan, Jefferson Y. ; Tarabay, Jana ; Zhao, Xiaohui

2024-11-01·CLINICAL CANCER RESEARCH

Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer

Article

作者: Perez, Kimberly ; Surana, Rishi ; Xiu, Joanne ; Pishvaian, Michael J. ; Narayan, Raja R. ; Kapner, Kevin S. ; Wolpin, Brian M. ; Jordan, Alexander C. ; Farrell, Alex ; Yuan, Chen ; Huffman, Brandon M. ; Weinberg, Benjamin ; Dougan, Stephanie K. ; Singh, Harshabad ; Goel, Sanjay ; Cleary, James M. ; Dias Costa, Andressa ; Williams, Hannah L. ; Nowak, Jonathan A. ; Oberley, Matthew ; Raghavan, Srivatsan ; Aguirre, Andrew J. ; Shroff, Rachna T. ; Spetzler, David ; Sledge, George

Abstract:

Purpose::

Transcriptional profiling of pancreatic cancers has defined two main transcriptional subtypes: classical and basal. Initial data suggest shorter survival for patients with basal tumors and differing treatment sensitivity to FOLFIRINOX and gemcitabine plus nab-paclitaxel by transcriptional subtype.

Experimental Design::

We examined 8,743 patients with RNA sequencing from pancreatic cancers performed at Caris Life Sciences. Classical and basal subtypes were identified using purity independent subtyping algorithm on RNA sequencing, and two cohorts were analyzed: (i) the biomarker cohort included patients with complete molecular profiling data (n = 7,250) and (ii) the outcome cohort included patients with metastatic disease with available survival outcomes (n = 5,335). A total of 3,842 patients were shared between the two cohorts. Kaplan–Meier curves and Cox proportional hazards regression were used to assess patient survival.

Results::

In the biomarker cohort, 3,063 tumors (42.2%) were strongly classical (SC) and 2,015 tumors (27.8%) were strongly basal (SB). SC and SB tumors showed strong associations with histologic phenotypes and biopsy sites. SB tumors had higher rates of KRAS, TP53, and ARID1A mutations, lower rates of SMAD4 mutation, and transcriptional evidence of epithelial-mesenchymal transition. Sixty of 77 cases (78%) maintained their transcriptional subtype between temporally and/or spatially disparate lesions. In the outcome cohort, the SB subtype was associated with shorter overall survival time, regardless of whether they received FOLFIRINOX or gemcitabine plus nab-paclitaxel as first-line chemotherapy. The mutant KRAS allele type was prognostic of outcomes; however, this impact was restricted to SC tumors, whereas all mutant KRAS alleles had similarly poor outcomes in SB tumors.

Conclusions::

The SB subtype is a strong independent predictor of worse outcomes, regardless of the up-front chemotherapy regimen used. Clinical trials should further investigate pancreatic cancer transcriptional subtypes as a prognostic and predictive biomarker.

2024-09-01·GYNECOLOGIC ONCOLOGY

A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma

Article

作者: Wu, Sharon ; Khabele, Dineo ; Phung, Thuy ; Wilhite, Annelise M ; Pierce, Jennifer Y ; Xiu, Joanne ; Rocconi, Rodney P ; Scalici, Jennifer M ; Erickson, Britt K ; Gibney, Geoffrey T ; Herzog, Thomas J ; Brown, Jubilee ; In, Gino K ; Jones, Nathaniel L

OBJECTIVE:

Our goal was to compare molecular and immune profiles of vulvovaginal melanoma (VVM) with cutaneous melanoma (CM) and explore the significance of immune checkpoint inhibitor (ICI) agents on survival.

METHODS:

Samples from VVM and CM tumors underwent comprehensive molecular and immune profiling. Treatment and survival data were extracted from insurance claims data and OS was calculated from time of ICI treatment to last contact. Statistical significance was determined using chi-square and Wilcoxon rank sum test and adjusted for multiple comparisons.

RESULTS:

Molecular analysis was performed on 142 VVM and 3823 CM tumors. VVM demonstrated significantly (q < 0·01) less frequent BRAF and more frequent KIT, ATRX, and SF3B1 mutations. Alterations in pathways involving DNA damage and mRNA splicing were more common in VVM, while alterations in cell cycle and chromatin remodeling were less common. Immunogenicity of VVM was lower than CM, with an absence of high TMB (0% vs 46.9%) and lower PD-L1 positivity (18·0% vs 29·5%). Median immune checkpoint gene expression was lower in VVM, as were cell fractions for type I macrophages and CD8+ T-cells(q < 0·01). Myeloid dendritic cells were increased in VVM(q < 0·01). Median OS was shorter for VVM than for CM patients treated with ICIs (17·6 versus 37·9 months, HR:1·65 (95% CI 1·02-2·67) p = 0·04).

CONCLUSIONS:

VVM has a distinct molecular and immune profile compared to CM, which may contribute to the worse survival in VVM compared to CM patients treated with ICI therapy. Though ICIs have been a mainstay of treatment in recent years, our findings suggest that new therapeutic strategies are needed.

188

项与 Caris Life Sciences, Inc. 相关的新闻（医药）

2025-05-23

·PRNewswire

Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering

IRVING, Texas, May 23, 2025 /PRNewswire/ -- Caris Life Sciences® ("Caris"), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ("SEC") relating to a proposed initial public offering of its Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caris has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "CAI." BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC will act as lead book-running managers for the proposed offering. Citigroup will also act as a book-running manager for the proposed offering. TD Cowen, Evercore ISI and Guggenheim Securities will act as additional book-running managers for the proposed offering. BTIG and Wolfe | Nomura Alliance will act as co-managers for the proposed offering. The proposed offering will be made available only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: [email protected]; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email: [email protected]; or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282 or by email: [email protected]. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Caris Life Sciences Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. Caris Life Sciences Media: Corporate Communications [email protected] 214.294.5606 SOURCE Caris Life Sciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2025-05-22

·PRNewswire

Caris Life Sciences to Highlight an Extensive Lineup of Research and Precision Oncology Collaborations at the 2025 American Society of Clinical Oncology Annual Meeting

Caris Life Sciences and the Caris POA collaborators will collectively present 37 abstracts IRVING, Texas, May 22, 2025 /PRNewswire/ -- Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators within the Caris Precision Oncology Alliance™ (Caris POA) will collectively present 37 abstracts across 16 tumor types at the upcoming 2025 American Society of Clinical Oncology Annual Meeting, from May 30 – June 3, in Chicago, IL. Continue Reading "This year's ASCO abstracts highlight the growing clinical value of integrated molecular profiling and real world data, particularly as AI tools transform how we diagnose and treat cancer," said Caris EVP and Chief Medical Officer George W. Sledge, Jr., MD. "The data from our internal and collaborative studies show that we are entering a new era of precision oncology, where every data point can support smarter, more personalized decision-making." Caris Life Sciences and the Caris POA collaborators will collectively present 37 abstracts across 16 tumor types Post this "Caris' strong presence at ASCO demonstrates our ongoing commitment to revolutionizing healthcare and improving patient outcomes," said James Hamrick, MD, MPH, Chairman of the Caris Precision Oncology Alliance. "Caris' comprehensive clinicogenomic database helps enable novel insights into cancer and, together with our network of Caris POA researchers, is truly making an impact on patients' diagnosis, prognosis, care plans and responses to treatment." Oral presentation: CLONEVO: Preoperative abemaciclib for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) with molecular response assessment. (Abstract 4520) May 31, 2:15 – 2:21 PM CDT: Arie Crown Theater Poster presentations: Assessment of age in the clinical risk stratification of patients with IDH-mutant gliomas. Abstract: 2058 Poster Board: 104 May 31, 9:00 AM CDT: Hall A Comparing ERK signaling and tumor microenvironment in BRAF-altered gliomas. Abstract: 2063 Poster Board: 109 May 31, 9:00 AM CDT: Hall A Association of MGMT status with survival in low and high-grade IDH-mutant astrocytomas. Abstract: 2065 Poster Board: 111 May 31, 9:00 AM CDT: Hall A Prognostic impact of DDR mutations (mt) in IDH mutant high-grade gliomas (HGG). Abstract: 2066 Poster Board: 112 May 31, 9:00 AM CDT: Hall A Immune checkpoint inhibition in EBV-associated gastric cancer: A multi-center international retrospective analysis. Abstract: 4043 Poster Board: 333 May 31, 9:00 AM CDT: Hall A Molecular profile of hepatocellular carcinoma (HCC) in older (OA) versus younger adults (YA) receiving tyrosine kinase inhibitors: Does age matter? Abstract: 4124 Poster Board: 414 May 31, 9:00 AM CDT: Hall A The differential effect of stromal genes on gemcitabine/nab-paclitaxel (GN) and GN/cisplatin (GCN) outcomes in advanced pancreatic adenocarcinoma (aPDAC). Abstract: 4166 Poster Board: 456 May 31, 9:00 AM CDT: Hall A Biomarkers of response to immunotherapy in pancreatic ductal adenocarcinoma (PDAC) with homologous recombination deficiency (HRD). Abstract: 4176 Poster Board: 466 May 31, 9:00 AM CDT: Hall A Gamma secretase inhibitors and desmoid fibromatosis: Lessons from a real world, comprehensive genomic study of desmoids and CTNNB1/APC mutated soft tissue tumors. Abstract: 11547 Poster Board: 30 May 31, 9:00 AM CDT: Hall A Unveiling drivers of MHC repression and therapeutic strategies to counter immune evasion in small cell lung cancer. Abstract: 8091 Poster Board: 212 May 31, 1:30 PM CDT: Hall A Clinical outcomes and characterization of HER2 alterations in non-small cell lung cancer (NSCLC). Abstract: 8538 Poster Board: 18 May 31, 1:30 PM CDT: Hall A PRESCIENTai, an AI-based digital histopathological image signature for risk of late distant recurrence and extended endocrine therapy (EET) benefit in hormone-receptor-positive breast cancer. Abstract: 1556 Poster Board: 322 June 1, 9:00 AM CDT: Hall A Interferon signaling and outcomes in triple-negative breast cancer (TNBC) in FinXX, CALGB 40603 (Alliance) and real-world clinico-genomic data. Abstract: 569 Poster Board: 162 June 2, 9:00 AM CDT: Hall A MHC class I expression and outcomes in breast cancer in the real-world clinico-genomic data and the FinXX trial. Abstract: 570 Poster Board: 163 June 2, 9:00 AM CDT: Hall A Evaluation of tumor immune microenvironment in Hispanic and African American breast cancer. Abstract: 1051 Poster Board: 30 June 2, 9:00 AM CDT: Hall A Comparing clinical benefit of trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in a large cohort of HER2-negative metastatic breast cancer (MBC). Abstract: 1076 Poster Board: 55 June 2, 9:00 AM CDT: Hall A Steroid receptor expression and overall survival in breast cancer patients with ER+ bone metastasis: A retrospective review. Abstract: 1077 Poster Board: 56 June 2, 9:00 AM CDT: Hall A Multiomic Profiling of LRRC15 in Triple Negative Breast Cancer (TNBC). Abstract: 1098 Poster Board: 77 June 2, 9:00 AM CDT: Hall A Chemokines as predictive biomarkers for immune checkpoint inhibitor (ICI) benefit in triple negative breast cancer (TNBC). Abstract: 1106 Poster Board: 85 June 2, 9:00 AM CDT: Hall A Comprehensive molecular and immune characterization of adrenergic stress-signaling receptor ADRB2 in triple negative breast cancer (TNBC). Abstract: 1107 Poster Board: 86 June 2, 9:00 AM CDT: Hall A Comprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC). Abstract: 1114 Poster Board: 93 June 2, 9:00 AM CDT: Hall A HIF family transcription factor expression in a cohort of 4362 patients with renal cell carcinoma (RCC). Abstract: 4543 Poster Board: 343 June 2, 9:00 AM CDT: Hall A Real-world analysis of 2IR immune response score in histologic subtype urothelial carcinoma (hsUC). Abstract: 4568 Poster Board: 368 June 2, 9:00 AM CDT: Hall A Prevalence of histology-agnostic biomarkers in pure squamous cell carcinomas of the genitourinary tract. Abstract: 4609 Poster Board: 409 June 2, 9:00 AM CDT: Hall A Comprehensive genomic profiling of Black and non-Hispanic White (NHW) men with prostate cancer (PCa). Abstract: 5022 Poster Board: 221 June 2, 9:00 AM CDT: Hall A Effect of HLA class I expression on the tumor immune microenvironment and prognosis in prostate cancer. Abstract: 5044 Poster Board: 243 June 2, 9:00 AM CDT: Hall A Molecular and clinical characterization of KLK2 mRNA expression in prostate cancer (PC). Abstract: 5050 Poster Board: 249 June 2, 9:00 AM CDT: Hall A Prognostic relevance of Aurora kinase A (AURKA) expression in prostate cancer (PCa). Abstract: 5061 Poster Board: 260 June 2, 9:00 AM CDT: Hall A Molecular characterization of STEAP1 and -2 in advanced prostate cancer. Abstract: 5072 Poster Board: 271 June 2, 9:00 AM CDT: Hall A Characterization and impact of B7-H3 (CD276) expression across disease states and racial groups in prostate cancer. Abstract: 5073 Poster Board: 272 June 2, 9:00 AM CDT: Hall A Survival association of PIK3CA in HPV-driven head and neck squamous cell carcinoma (HNSCC). Abstract: 6056 Poster Board: 464 June 2, 9:00 AM CDT: Hall A Comparative transcriptomic analysis to identify similarities and therapeutic vulnerabilities in olfactory neuroblastoma (ONB), sinonasal neuroendocrine carcinoma (SNEC) and sinonasal undifferentiated carcinoma (SNUC). Abstract: 6095 Poster Board: 503 June 2, 9:00 AM CDT: Hall A BRAF -V600E papillary thyroid cancer: Updated analysis of real-world patient data. Abstract: 6099 Poster Board: 507 June 2, 9:00 AM CDT: Hall A Clinical significance of the CGRP pathway gene expression in advanced solid tumors: A sub-analysis of MONSTAR-SCREEN-2. Abstract: 2629 Poster Board: 276 June 2, 1:30 PM CDT: Hall A Effect of elevated expression of LILRB4 and TSC22D3 on survival in lung cancer. Abstract: 2633 Poster Board: 280 June 2, 1:30 PM CDT: Hall A Regorafenib response prediction in metastatic colorectal cancer by a novel genomic and transcriptomic model. Abstract: 3135 Poster Board: 450 June 2, 1:30 PM CDT: Hall A Poster and abstract summaries highlighting this research will be available onsite at Caris' booth #23093. The full abstracts will be available on the Caris website following the presentation. The Caris POA, a community of investigators, includes 97 cancer centers, academic institutions, research consortia and healthcare systems, including 45 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research. Caris and POA members work together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. About Caris Life Sciences Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multimodal database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides a differentiated platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. To learn more, please visit CarisLifeSciences.com. Caris Life Sciences Media: Corporate Communications [email protected] 214.294.5606 SOURCE Caris Life Sciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

ASCO会议免疫疗法

2025-05-12

·PRNewswire

Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients

IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as standard of care for all non-squamous non-small cell lung cancer (NSQ NSCLC) patients and is poised for future drug approvals. This advanced testing protocol aims to provide deeper insights into the molecular characteristics of NSQ NSCLC, facilitating more personalized and effective treatment strategies. Approximately 50% of NSQ NSCLCs lack a targetable gene driver mutation, making MET protein expression an important additional personalized target. Caris is addressing these challenges by leveraging the power of MET IHC testing, which evaluates the expression of the MET protein in cancer cells. This protein is known to play a crucial role in cell proliferation, invasion, and survival, making it a vital biomarker for targeted therapies. "To our knowledge, Caris is the only lab in the US that has historically and is currently offering the MET (SP44) RxDx assay for NSQ NSCLC," said Caris President David Spetzler, MS, PhD, MBA. "With MET IHC testing already in place, we are poised and ready to provide a detailed molecular profile to inform targeted therapies and future drug development approvals." Key Highlights of MET IHC Testing: Comprehensive Molecular Profiling: Caris utilizes a multi-platform approach, including immunohistochemistry (IHC) and next-generation sequencing (NGS), to provide a detailed molecular profile of NSQ NSCLC tumors. Identification of Actionable Targets: The MET IHC testing helps identify overexpression of the MET protein, which is associated with poor prognosis and can be targeted by specific therapies. Enhanced Treatment Personalization: By understanding the molecular makeup of NSQ NSCLC tumors, oncologists can tailor treatment plans to the individual needs of patients, potentially improving outcomes and quality of life. Caris remains committed to advancing cancer diagnostics and treatment through innovative technologies and rigorous scientific research. Deployment of MET IHC testing for NSQ NSCLC patients underscores this commitment and highlights Caris' dedication to improving patient care and outcomes. Caris' comprehensive molecular profile testing includes MI Cancer Seek® and Caris Assure®. Caris received FDA approval in November of 2024 for MI Cancer Seek®, a tissue-based assay which is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. Caris Assure® is a powerful blood-based assay that uniquely identifies somatic tumor, incidental clonal hematopoiesis and incidental germline variants by sequencing both plasma and buffy coat through a WTS and WES-based assay. About Caris Life Sciences Caris Life Sciences® (Caris) is a leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, multimodal database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides a differentiated platform to deliver the next generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with a vision to realize the potential of precision medicine in order to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. To learn more, please visit CarisLifeSciences.com. Caris Life Sciences Media: Corporate Communications [email protected] 214.294.5606 SOURCE Caris Life Sciences WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 项与 Caris Life Sciences, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Caris Life Sciences, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年06月07日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

C10.36	肿瘤更多	药物发现
利妥昔单抗 ( CD20 )	复发性弥漫性大B细胞淋巴瘤更多	无进展
环磷酰胺 ( DNA )	低级别 B 细胞非霍奇金淋巴瘤更多	无进展
喷司他丁 ( ADA )	低级别 B 细胞非霍奇金淋巴瘤更多	无进展